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Introduction
Toll-like receptors (TLR) on the surface of cells of the 
respiratory tract play an essential role in sensing the 
presence of microorganisms in the airways and lungs. 
Th   ese receptors trigger inﬂ  ammatory responses, activate 
innate immune responses, and prime adaptive immune 
responses to eradicate invading microbes [1]. TLR are 
members of a family of pattern-recognition receptors, 
which recognize molecular structures of bacteria, viruses, 
fungi and protozoa (pathogen-associated molecular 
patterns or PAMPs), as well as endogenous structures 
and proteins released during inﬂ  ammation  (damage/
danger-associated molecular patterns or DAMPs). To 
date, ten diﬀ  erent TLR have been identiﬁ  ed in humans 
and twelve in mice. TLR are expressed on all cells of the 
immune system, but also on parenchymal cells of many 
organs and tissues. Th  e binding of a PAMP to a TLR 
results in cellular activation and initiates a variety of 
eﬀ   ector functions, including cytokine secretion, proli-
fera  tion, co-stimulation or phagocyte maturation. To 
facilitate microbial recognition and to amplify cellular 
responses, certain TLR require additional proteins, such 
as lipopolysaccharide (LPS) binding protein (LBP), CD14, 
CD36 and high mobility group box-1 protein (HMGB-1). 
In this chapter, the role of CD14 as an accessory receptor 
for TLR in lung inﬂ  ammation and infection is discussed. 
Th  e central role of CD14 in the recognition of various 
PAMPs and ampliﬁ  cation of immune and inﬂ  ammatory 
responses in the lung is depicted in Figure 1.
CD14 was characterized as a receptor for bacterial 
endotoxin (LPS) in 1990, almost a decade before the dis-
covery and characterization of TLR, and can be regarded 
as the ﬁ  rst described pattern-recognition receptor [2]. 
Th   e protein was ﬁ  rst identiﬁ  ed as a diﬀ  erentiation marker 
on the surface of monocytes and macrophages and was 
designated CD14 at the ﬁ  rst leukocyte typing workshop 
in Paris in 1982. Th   e genomic DNA of human CD14 was 
cloned in 1988 and the gene was later mapped to 
chromo  some 5q23–31. Several polymorphisms have 
been found in the CD14 gene, of which nucleotide poly-
morphisms at position –159 and –1619 correlated with 
decreased lung function in endotoxin-exposed farmers [3].
Th   e CD14 gene consists of two exons which code for a 
single mRNA that is translated into a protein of 375 amino 
acids. Th   e CD14 protein is composed of eleven leucin-rich 
repeats, which are also found in TLR and which are 
important in PAMP binding. Moreover, the crystal 
structure of CD14 revealed that the protein has a `horse-
shoe’ shape, similar to TLR4, and that LPS is bound within 
the pocket [4]. In contrast to TLR, however, CD14 lacks a 
transmembrane domain, and thus cannot initiate 
intracellular signal transduction by itself. Th  e CD14 
protein is processed in the endoplasmatic reticu  lum and 
expressed as a 55 kDa glycoprotein on the cell surface via a 
glycosylphosphatidyl (GPI) anchor [5]. Like other GPI-
anchored proteins, CD14 accumulates on the cell surface 
in microdomains known as lipid rafts, which are fairly rich 
in cholesterol and accumulate several kinases at the 
intracellular site. CD14 is expressed pre  dominantly on the 
surface of `myeloid’ cells, such as mono  cytes, macrophages 
and neutrophils, but at lower levels also on epithelial cells, 
endothelial cells and ﬁ  broblasts.
In addition to being expressed as a GPI-anchored 
membrane protein, CD14 is also expressed in a soluble 
form (sCD14) [2]. sCD14 may result from secretion of 
the protein before coupling to the GPI anchor or from 
shedding or cleavage from the surface of monocytes. 
sCD14 is present in the circulation and other body ﬂ  uids 
and levels of sCD14 in plasma increase during inﬂ  am-
mation and infection. Since interleukin (IL)-6 induces 
sCD14 expression in liver cells it is regarded as an acute 
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from patients with acute respiratory distress syndrome 
(ARDS), sCD14 levels were strongly increased and 
correlated with total protein levels and neutrophil 
numbers in the BAL ﬂ   uid [6], suggesting that sCD14 
contributes to the inﬂ  ammatory process in the lung.
CD14 is a molecule with a wide range of functions. In 
addition to functioning as a pattern recognition receptor 
for a variety of microbial ligands, CD14 also acts as a 
receptor for endogenous molecules like intercellular 
adhesion molecule (ICAM)-3 on the surface of apoptotic 
cells, amyloid peptid, ceramide, and urate crystals. 
Ligation of CD14 by these ligands, except for apoptotic 
cells, mediates activation of inﬂ  ammatory responses.
CD14 and the LPS receptor complex
LPS is the major constituent of the outer membrane of 
Gram-negative bacteria and is one of the most potent 
TLR ligands. CD14 together with LBP plays an essential 
role in binding of LPS to the TLR4/MD-2 complex [7]. 
LBP, which, among others, is present in the bloodstream 
and BAL ﬂ  uid [8], binds to LPS aggregates and transfers 
LPS monomers to CD14. CD14 associates with TLR4/
MD-2 and transfers the LPS monomer to this complex 
[7]. Likewise, sCD14 is able to mediate LPS-activation 
of cells with low membrane CD14 expression, such as 
epithelial and endothelial cells [9]. However, at high 
con  cen  trations, LBP and sCD14 are also able to 
downregulate LPS-induced responses by transfer of LPS 
to lipoproteins for subsequent removal [10]. Recent data 
indicate that LPS is bound by MD-2 within the TLR4/
MD-2 complex [11] and that subsequent conformational 
changes in TLR4 lead to reorganization of its cyto-
plasmic domain, enabling the recruitment of the adaptor 
proteins, myeloid diﬀ  erentiation  primary-response 
protein 88 (MyD88) and TIR-domain-containing-adaptor-
protein-inducing-inter feron  (IFN)-β (TRIF) [12]. Th  ese 
adaptors initiate signal transduction to the nucleus by 
activation of nuclear factor (NF)-κB and IFN regulatory 
transcription factor (IRF)-3, leading to the production 
of cytokines that regulate inﬂ  ammatory cells [12]. In 
macrophages, TRIF-dependent signaling is essential for 
the expression of the majority of LPS-induced genes, 
including IFN-α/β.
Figure 1. Central role of CD14 in pathogen- and pathogen-associated molecular pattern (PAMP)-induced responses in the lung. 
CD14, which lacks an intracellular domain for signal transduction, is expressed on the surface of alveolar macrophages, infi  ltrating monocytes and 
neutrophils, and at lower levels also on epithelial and endothelial cells in the lung. CD14 recognizes and binds various structures from invading 
microbes, such as lipopolysaccharide (LPS) from Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, lipoarabinomannan 
(LAM) from mycobacteria, viral double stranded (ds) RNA and F glycoprotein (F-gp) from respiratory syncytial virus (RSV). CD14 subsequently 
transfers these bound components to Toll-like receptors (TLR) which than trigger cell activation. Binding of LPS to CD14 is regulated by additional 
accessory receptors in the lung, including LPS-binding protein (LBP) and a number of surfactant proteins (SP). Furthermore, soluble CD14 (sCD14) 
enhances LPS-induced activation of cells with low CD14 expression. Depending on the microbe and the PAMPs it expresses, CD14-amplifi  ed 
responses can either be benefi  cial to the host by induction of an adequate infl  ammatory and immune response to eradicate the invading microbe, 
or detrimental to the host by excessive infl  ammation and/or dissemination of the pathogen.
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the TLR4/MD-2 complex can distinguish between diﬀ  er-
ent chemotypes of LPS [13]. Smooth LPS is synthesized 
by most Gram-negative bacteria and consists of three 
modules: Th   e lipid A moiety, a core poly  saccharide, and 
an O-polysaccharide of variable length (made up of 1 to 
over 50 monosaccharide units) [7]. Gram-negative bacteria 
that fail to add the core polysaccharide or the O-poly-
saccharide chain to the lipid A moiety produce `rough’ 
LPS, named after the rough morphology of the colonies 
these bacteria form. Lipid A, the bioactive part of both 
smooth and rough LPS, is responsible for most of the 
pathogenic eﬀ  ects in Gram-negative bacterial infections 
[7, 12]. Murine macrophages lacking CD14 secreted equal 
amounts of tumor necrosis factor-α (TNF) to macro-
phages expressing CD14 upon stimulation with rough 
LPS, but failed to secrete TNF in response to smooth 
LPS, an eﬀ  ect which was reversed by addition of sCD14 
[13]. Moreover, macrophages lacking CD14 failed to 
secrete IFN-α/β in response to either rough or smooth 
LPS. Th  ese ﬁ  ndings indicate that CD14 is required for 
activation of the TLR4/TRIF pathway by either smooth 
or rough LPS, and required for the activation of TLR4/
MyD88 pathway by smooth but not by rough LPS [13]. In 
addition to LPS, CD14 also facilitates TLR4 activation by 
other PAMPs including certain viral components [13, 14].
In the lung, binding of LPS to TLR4 is inﬂ  uenced by a 
number of surfactant proteins (SP), including SP-A, SP-C 
and SP-D [15]. Th   ese surfactants are able to inﬂ  uence the 
interaction between TLR4 and LPS by direct binding to 
LPS; i.e., SP-A binds to rough LPS and lipid A, but not to 
smooth LPS, SP-C also binds to rough LPS, and SP-D 
binds to both rough and smooth LPS. SP-A and SP-C 
binding to LPS inhibits TNF secretion by alveolar macro-
phages, whereas SP-D binding to LPS moderately 
enhances TNF secretion by alveolar macrophages. In 
addition, SP-A, SP-C and SP-D also bind to CD14 at the 
site which recognizes LPS. Strikingly, binding of SP-A to 
CD14 enhanced the binding of rough LPS and binding of 
SP-C to CD14 augmented binding of smooth LPS [15], 
whereas binding of SP-A to CD14 reduced binding of 
smooth LPS and binding of SP-D to CD14 decreased 
binding of both smooth and rough LPS. Furthermore, 
SP-D inﬂ  uences LPS-induced TNF secretion by alveolar 
macrophages by regulating matrix metalloproteinase-
mediated cleavage of CD14 from the surface of these cells 
[16].
Together, these ﬁ  ndings suggest that LPS recognition in 
the lung and subsequent induction of inﬂ  ammatory 
immune response is a complexly regulated process.
CD14 and other pattern recognition receptors
In addition to LPS-induced activation of TLR4, CD14 
also ampliﬁ   es a number of TLR-dependent responses 
triggered by other bacterial PAMPs, including peptido-
glycan, lipoteichoic acid (LTA) and lipoarabinomannan 
(LAM) [17–19].
Peptidoglycan is an essential cell wall component of 
virtually all bacteria. Peptidoglycan is a polymer of N-
acetylglucosamine and N-acetylmuramic acid, cross-
linked by short peptides. Breakdown products of 
peptido  glycan are recognized by diﬀ   erent classes of 
pattern-recognition receptors [19]. Polymeric soluble 
peptidoglycan is recognized by TLR2 on the surface of 
cells, and the interaction of peptidoglycan with TLR2 
triggers MyD88-dependent activation and nuclear trans-
location of NF-κB, and subsequently the transcription 
and secretion of cytokines. Muramyl dipeptide and γ-D-
glutamyl-meso-diaminopimelic acid, which are low-
molecular weight breakdown fragments of peptidoglycan, 
are recognized by intracellular pathogen recognition 
receptors, nucleotide-binding oligomerization domain 
containing (Nod)2 and Nod1, respectively [19]. Ligand 
binding to these receptors triggers interaction with the 
receptor-interacting protein kinase, RIP2, which activates 
NF-κB. Of these peptidoglycan breakdown products, 
only polymeric peptidoglycan binds to CD14, and CD14 
enhances polymeric peptidoglycan-induced TLR2 activa-
tion. Th  e low molecular weight fragments of peptido-
glycan, like muramyl dipeptide, do not bind to CD14, do 
not induce cell activation through CD14 and also do not 
interfere with the binding of polymeric peptidoglycan to 
CD14 [19]. Furthermore, unlike LPS, peptidoglycan 
bound to sCD14 is not able to activate epithelial and 
endothelial cells with low membrane CD14 expression.
LTA is a constituent of the cell wall of Gram-positive 
bacteria, anchored on the outer face of the cytoplasmic 
membrane and commonly released during growth and 
antibiotic therapy. Like polymeric peptidoglycan, LTA 
induces NF-κB activation and cytokine secretion in a 
TLR2-dependent manner. LTA is recognized by LBP and 
CD14, and these accessory receptors both enhance LTA-
induced cell activation [18]. Presumably in a similar 
manner, CD14 also enhances TLR2-dependent cellular 
activation by LAM derived from the cell-wall of 
mycobacteria. LAM derived from slowly growing virulent 
mycobacteria like Mycobacterium tuberculosis and 
M. leprae is capped with mannose (ManLAM), whereas 
LAM from avirulent and fast growing mycobacterial 
species is uncapped (AraLAM). Strikingly, AraLAM from 
avirulent mycobacteria is much more potent in inducing 
TNF secretion by macrophages than ManLAM from 
virulent mycobacterial strains [12]. AraLAM-, but not 
ManLAM-induced TNF secretion by monocytes and 
macrophages was largely CD14-, TLR2- and MyD88-
dependent [17].
Recently CD14 was also found to enhance the innate 
immune response triggered by the TLR3 ligand poly(I:C), 
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together with TLR7 and TLR8 are regarded as sensors for 
viral infection, since these receptors recognize viral 
nucleic acids, like single and double stranded RNA. Th  e 
potentiating eﬀ  ect of CD14 on TLR3 activation resulted 
from increased uptake of poly(I:C) and intracellular 
delivery to the compartment where TLR3 resides [20]. 
Taken together, these ﬁ  ndings suggest that CD14 plays an 
important role in the induction and ampliﬁ  cation  of 
inﬂ   ammatory responses evoked by a wide variety of 
pathogens.
Role of CD14 in LPS- and LTA-induced lung 
infl  ammation
Th  e contribution of CD14 to TLR ligand-induced lung 
inﬂ   ammation has been investigated in several animal 
studies (Table 1). Intratracheal administration of LPS did 
not signiﬁ   cantly induce TNF release and neutrophil 
accumulation in the lungs of rabbits, unless LPS was 
complexed with LBP [21] or the animals were subjected 
to mechanical ventilation [22]. Intratracheal instillation 
of anti-CD14 antibodies together with LPS/LBP or 
intravenous pretreatment with anti-CD14 or anti-TLR4 
antibodies before mechanical ventilation markedly 
reduced these inﬂ  ammatory responses [21, 22]. Despite a 
reduction in lung neutrophil number, intravenous anti-
CD14 treatment of rabbits exposed to LPS and subjected 
to ventilation did not cause a decrease in lung 
chemokines, including CXCL8 (IL-8), growth related 
oncogene (GRO) and monocyte chemoattractant protein 
(MCP)-1, whereas anti-TLR4 treatment did lower the 
level of GRO moderately and of CXCL8 signiﬁ  cantly [22]. 
Th  ese ﬁ   ndings reveal that LPS alone does not cause 
signiﬁ  cant lung inﬂ  ammation in rabbits and suggest that 
additional accessory signals are required. Whether 
mechanical ventilation induces increased release of LBP 
or release of (endogenous) DAMPs which potentiate the 
LPS-induced response remains to be determined.
In contrast to rabbits, administration of LPS alone to 
lungs of naive mice induced severe pneumonitis, irres-
pective of the manner of LPS delivery (inhalation or 
intra  tracheal or intranasal instillation) or the source of 
LPS (Escherichia coli or Acinetobacter baumannii). Using 
antibody-treated and gene-deﬁ   cient mice, CD14 was 
found to be critically involved in the development of 
LPS-induced lung inﬂ  ammation [23–26]. A study with 
CD14-deﬁ  cient mice and TLR4 mutant mice (lacking a 
functional TLR4) showed that LPS-induced vascular 
leakage, neutrophil inﬁ  ltration, nuclear translocation of 
NF-κB. Th  e release of cytokines (TNF and IL-6) and 
chemo  kines (CXCL1 and CXCL2) in the lung was 
completely dependent on these pattern recognition 
receptors [24]. Similar observations were made by others 
using mice treated intravenously with anti-CD14 
Table 1. Eff  ect of CD14 `neutralization’ in lung infl  ammation and lung infection
Inciting ligand/pathogen  Animal model*  Eff  ect of CD14 `neutralization’ in the lung**  Ref.
LPS (E. coli +LBP)  rabbit αCD14  neutrophil infl  ux, cytokines 21
LPS (E. coli +ventilation)    neutrophil infl  ux, ~chemokines 22
LPS (E. coli) mouse  αCD14  neutrophil infl  ux, vascular leakage, NF-κB activation  23
LPS (E. coli) mouse  CD14-/-  neutrophil infl  ux (reversed by sCD14), cytokines (restored by sCD14),   24, 26
   chemokines, vascular leakage
LPS (A. baumannii)   neutrophil infl  ux, cytokines 25
LTA (S. aureus) mouse  CD14-/-  ~neutrophil infl  ux, cytokines, chemokines 28
LTA (S. pneumoniae)   neutrophil infl  ux, ~cytokines, ~chemokines 29
nontypeable H. infl  uenza mouse  CD14-/-  clearance, (early) (late) neutrophil infl  ux, (early) (late) cytokines  30
A. baumannii mouse  CD14-/-  clearance, ~neutrophil infl  ux, ~cytokines (dissemination) 25
E. coli rabbit  αCD14  clearance, ~neutrophil infl  ux, ~cytokines,   32
   ~chemokines (systemic responses)
B. pseudomallei mouse  CD14-/-  clearance (reversed by sCD14), neutrophil infl  ux (reversed by sCD14),   40
   ~cytokines (systemic clearance (reversed by sCD14)) (mortality)
S. pneumoniae mouse  CD14-/-  clearance (reversed by sCD14), neutrophil infl  ux, cytokines,   41
   chemokines ( dissemination (reversed by sCD14)) 
   ( mortality (reversed by sCD14))
M. tuberculosis mouse  CD14-/-  ~clearance, cellular infi  ltration, ~/cytokines (mortality) 44
Infl  uenza A  mouse CD14-/-  /~clearance, ~lymphocyte recruitment and activation, ~neutrophil infl  ux,   50
   ~cytokines
* αCD14: anti-CD14 antibody treatment; CD14-/-: CD14-gene defi  cient. ** (): (strongly) reduced; ~: unaltered; (): (strongly) increased. LPS = lipopolysaccharide; 
LTA = lipoteichoic acid.
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and TLR4-deﬁ  cient mice [25]. Furthermore, intratracheal 
treatment of CD14-deﬁ  cient mice with sCD14 restored 
the inﬂ  ammatory response to the level present in wild-
type mice, whereas treatment with wild-type alveolar 
macrophages restored the neutrophil inﬁ  ltration of the 
lung but not pulmonary TNF release [26]. Moreover, 
treatment with wild-type alveolar macrophages also 
restored neutrophil inﬁ   ltration in the lung of LPS-
exposed TLR4-deﬁ   cient mice [27]. Th  ese  ﬁ  ndings 
indicate that sCD14, and CD14 and TLR4 on the surface 
of alveolar macrophages contribute to the development 
of LPS-induced lung inﬂ   ammation. However, when a 
high dose of LPS was administered to the lungs of mice, 
acute lung inﬂ   ammation was absent in mice lacking 
functional TLR4, but only partially reduced in CD14 
deﬁ  cient mice [24]. Th  us, LPS-induced lung inﬂ  am  ma-
tion is entirely dependent on TLR4 and, depending on the 
dose of LPS, also on the presence of CD14 in the lung.
Our group determined whether CD14 also contributes 
to the development of lung inﬂ   ammation induced by 
LTA, a TLR2 ligand from the cell wall of Gram-positive 
bacteria [28, 29]. Lung inﬂ   ammation induced by 
Staphylo coccus  aureus LTA was completely dependent on 
TLR2, but independent of LBP and only moderately 
dependent on CD14 expression. As compared to wild-
type mice, S. aureus LTA-induced neutrophil inﬂ  ux was 
unchanged in CD14-deﬁ   cient mice, whereas TNF and 
CXCL2 release in the lung were partially reduced [28]. 
Strikingly, however, pulmonary inﬂ   ammation was also 
greatly diminished in TLR4-deﬁ  cient mice, as well as in 
mice deﬁ   cient for platelet activating factor receptor 
(PAFR), a known receptor for LTA on epithelial cells. 
Similarly, lung inﬂ   ammation induced by Streptococcus 
pneumoniae LTA, which is less potent compared 
S. aureus LTA, was also completely dependent on TLR2 
expression. However, in contrast to S. aureus LTA, 
neutrophil inﬁ   ltration of the lung was moderately 
reduced in CD14-deﬁ   cent mice treated with pneumo-
coccal LTA, whereas TNF and CXCL2 release in the lung 
was unchanged [29]. Moreover, pneumococcal LTA-
induced lung inﬂ  ammation was moderately diminished 
in TLR4-deﬁ   cient mice. Th  us, despite the amplifying 
eﬀ   ect on LTA-induced TLR2-mediated responses in 
vitro, CD14 contributes minimally to lung inﬂ  ammation 
induced by LTA. Th  e unexpected contribution of TLR4 
to LTA-induced lung inﬂ   ammation may result from 
DAMPs generated during the inﬂ  ammatory process in 
the respiratory tract.
Role of CD14 in lung infection
In line with the ﬁ  ndings that CD14 contributes to LPS-
induced lung inﬂ  ammation in mice, a number of studies 
have shown that CD14 is essential for the host defense 
response in the lung against Gram-negative bacteria, such 
as nontypeable Haemophilus inﬂ  uenzae, a possible cause 
of community acquired pneumonia, and A.  baumannii 
and  E. coli, which are frequent inducers of nosocomial 
pneumonia (Table 1). Nontypeable H. inﬂ  uenzae expresses 
the TLR4 ligands LPS and lipooligosaccharide on its cell 
wall, as well as several TLR2 ligands, including lipo-
proteins and porins. Previously, we found that activa  tion 
of alveolar macrophages by nontypeable H. inﬂ  uenzae 
depended on expression of TLR4, TLR2, and CD14 [30]. 
Moreover, bacterial clearance after intranasal infection 
with nontypeable H. inﬂ  uenzae was markedly reduced in 
CD14-deﬁ  cient and TLR4-deﬁ  cient mice, as well as in 
TLR2-deﬁ  cient mice at later stages of the disease [30]. 
Interestingly, despite impaired bacterial clearance in 
CD14-deﬁ  cient and TLR4-deﬁ  cient mice, the inﬂ  amma-
tory response in the lung was strongly reduced in TLR4 
deﬁ   cient mice, but elevated in CD14 deﬁ  cient  mice. 
Similar observations were made with encapsulated 
H. inﬂ  uenzae in TLR4-mutant mice [31]. Furthermore, 
clearance of nontypeable H. inﬂ  uenzae was also signiﬁ  -
cantly impaired in MyD88-deﬁ  cient mice, but not in mice 
lacking functional TRIF [30]. In a similar manner, CD14 
was involved in the host defense response against 
A.  baumanii [25]. CD14-deﬁ   cient mice, like TLR4-
deﬁ  cient mice, suﬀ  ered from impaired bacterial clearance 
in the lungs and enhanced bacterial dissemination after 
intranasal infection with A. baumannii. However, unlike 
TLR4-deﬁ   cient mice, CD14-deﬁ   cient mice developed 
similar inﬂ  ammatory responses compared to wild-type 
mice. Th  ese ﬁ  ndings suggest a role for CD14 in anti-
bacterial responses against nontypeable H. inﬂ  uenzae 
and A. baumannii. Although the role of TLR4 (and TLR2) 
in phagocytic killing is controversial, it is unknown 
whether CD14 is involved in such processes. Th   e role of 
CD14 in E. coli-induced pneumonia was determined in 
anti-CD14 antibody treated rabbits. Intravenous anti-
CD14 antibody treatment of rabbits inoculated with 
E.  coli by bronchial instillation, resulted in decreased 
bacterial clearance from the lungs, but had no eﬀ  ect on 
neutrophil inﬁ  ltration or cytokine release in the lungs 
[32]. However, anti-CD14 treatment protected against 
sustained hypotension and reduced the levels of nitrate 
and nitrite in the blood. Th  e contribution of CD14 to 
E. coli-induced pneumonia has not been investigated in 
mice, whereas the role of the other components of the 
LPS receptor complex (TLR4, MD-2, MyD88, TRIF) has 
been determined using gene-deﬁ  cient or mutant mice. 
Although analysis of bacterial clearance after intranasal 
infection of TLR4-mutant mice with E. coli produced 
inconsistent results [33], lack of MD-2 or TRIF resulted 
in impaired bacterial clearance after E. coli instillation in 
the lungs [34, 35]. Moreover, E. coli-induced neutrophil 
accumulation and cytokine release was signiﬁ  cantly 
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or TRIF [33–35]. Th  ese ﬁ  ndings indicate that signaling 
through the TLR4 receptor complex is essential in the host 
defense response against E. coli, and suggests that CD14 
may contribute to these E. coli-induced responses.
To our knowledge, it is unclear whether CD14 
contributes to host defense against Pseudomonas 
aeruginosa, a frequent cause of nosocomial pneumonia, 
and  Burkholderia cepacia, a prevalent Gram-negative 
bacterium, together with P. aeruginosa, in patients with 
cystic ﬁ  brosis. Recently, it was found that both TLR4 and 
TLR5 are critical in the host response to P. aeruginosa 
and that TLR4-deﬁ   cient mice were not susceptible to 
intratracheal  P. aeruginosa infection unless a bacterial 
mutant devoid of ﬂ  agellin production was used [36]. A 
similar approach is required to determine a role for CD14 
in Pseudomonas-induced pneumonia. It is plausible that 
CD14 also contributes to the host response against 
B. cepacia, since LPS from this bacterium signals through 
TLR4 and anti-CD14 antibodies dramatically inhibited 
B. cepacia-induced chemokine secretion by lung epithelial 
cells [37]. Whether CD14 contributes to host defense 
response against Klebsiella pneumoniae, a known cause 
of nosocomial pneumonia, also remains to be deter-
mined, but data from our study with TLR4-mutant mice 
indicate that signaling through TLR4 is essential for 
successful clearance of this bacterium [38].
In contrast to the essential role of pulmonary TLR4 and 
CD14 in the host defense response against most Gram-
negative bacteria, we found that TLR4 was not involved 
and CD14 played a remarkable detrimental role in the 
host response to B. pseudomallei, the causative organism 
of melioidosis (the most common cause of community-
acquired sepsis in Southeast Asia) [39, 40]. CD14-
deﬁ  cient mice infected intranasally with B. pseudomallei 
were protected from mortality, accompanied by 
enhanced bacterial clearance in the lung, blood and liver, 
and reduced cellular inﬁ  ltration in the lung [39], whereas 
the course of disease in TLR4-deﬁ  cient mice was indis-
tinguishable from wild-type mice [40]. Moreover, intranasal 
administration of sCD14 to CD14-deﬁ  cient mice partially 
reversed the phenotype into that of wild-type mice [40]. 
Interestingly, these ﬁ  ndings  in  B. pseudo  mallei-infected 
CD14-deﬁ  cient mice strongly resemble our previous results 
found with TLR2-deﬁ  cient mice, and are in line with the 
observation that B. pseudomallei expresses an atypical LPS 
which signals through TLR2 [39]. Whether CD14 interacts 
with TLR2 in B. pseudo  mallei-induced responses, and by 
which mechanism these receptors facilitate the growth and 
dissemination of B. pseudomallei after intranasal infection 
remains to be determined.
In the model for S. pneumoniae-induced pneumonia, 
we observed an unexpected detrimental role for CD14 in 
the innate host defense response. S. pneumoniae, a 
Gram-positive bacterium and the single most frequent 
pathogen causing community-acquired pneumonia, 
induces severe lung inﬂ  ammation and sepsis in wild-type 
mice after intranasal instillation. Strikingly, CD14-
deﬁ   cient mice were protected against pneumococcal 
pneumonia, presumably as a result of reduced bacterial 
spread to the circulation and reduced lung inﬂ  ammation 
[41]. In contrast, TLR2-deﬁ  cient and TLR4-mutant mice 
were not protected against pneumococcal pneumonia 
[38, 42], but in fact TLR2 seemed redundant for eﬃ   cient 
bacterial clearance and TLR4-mutant mice were more 
susceptible to pneumonia, accompanied by impaired 
bacterial clearance. However, as in CD14-deﬁ  cient mice, 
lung inﬂ   ammation was also reduced in pneumococci-
infected TLR2-deﬁ  cient mice [42]. Since intrapulmonary 
treatment with sCD14 rendered CD14-deﬁ  cient  mice 
equally susceptible to S. pneumoniae as wild-type mice 
[41], these results suggest that S. pneumoniae abuses (s)
CD14 in the lung to cause invasive respiratory tract 
infection. Interestingly, the phenotype of CD14 deﬁ  cient 
mice strongly resembled the phenotype of mice deﬁ  cient 
for PAFR [43], a receptor for phosphoryl choline from the 
pneumococcal cell wall which facilitates pneumococcal 
invasion of cells. Further studies are required to 
determine whether CD14 serves as a chaperone in the 
presentation of S. pneumoniae to the PAFR so that the 
phosphoryl–PAFR-mediated invasion is facilitated.
Since M. tuberculosis expresses a number of molecules, 
such as lipoproteins, which activate immune cells in a 
CD14-dependent manner, we and others investigated 
whether CD14 also contributed to the host immune 
response in mice with lung tuberculosis [44]. Although 
initially after intranasal infection of wild-type and CD14-
deﬁ   cient mice no diﬀ   erences in bacterial loads, cell 
inﬁ  ltration and release of most cytokines in the lung were 
found [44, 45], at later time points (> 20 weeks after 
infection) CD14-deﬁ   cient mice were protected from 
mortality presumably as a result of a reduced inﬂ  am-
matory response in the lungs [44]. Th  ese ﬁ  ndings  are 
completely opposite to the results from M. tuberculosis-
infected TLR2-deﬁ  cient and TLR4-mutant mice, which 
suﬀ   ered from reduced bacterial clearance, chronic 
inﬂ  ammation, increased cellular inﬁ  ltration of the lungs 
and reduced survival [46–48]. Th   e mechanism underlying 
the detrimental eﬀ   ect of CD14 in the host response 
against M. tuberculosis remains to be established.
In addition to its role in (myco)bacterial infections, 
CD14 may also play a role in the pulmonary host 
response against respiratory syncytial virus (RSV), the 
most common cause of lower respiratory tract disease in 
infants and young children worldwide, and inﬂ  uenza A 
virus, a cause of pneumonia in very young children, the 
elderly and immunocompromised patients. Th  e envelop 
F glycoprotein from RSV and certain inﬂ  uenza A virus 
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manner [14, 20]. Experiments with wild-type and TLR4-
mutant mice infected intranasally with RSV showed that 
viral clearance was reduced in the absence of functional 
TLR4 [14], due to impaired natural killer (NK) cell 
migration and function and impaired cytokine secretion. 
Recently, it was found that TLR2 and TLR6 are also 
involved in recognition of RSV [49]. Whether CD14 
contributes to these TLR-mediated immune responses 
against RSV remains to be determined. Using CD14-
deﬁ   cient mice, we demonstrated that CD14 played a 
minimal role in inﬂ  uenza A virus-induced pneumonia 
[50]. During the entire course of disease, viral loads were 
slightly reduced in CD14-deﬁ  cient mice, but this did not 
result from improved lymphocyte recruitment or 
lympho  cyte activation, or consistent changes in pulmo-
nary cytokines [50]. Th   us, despite the fact that inﬂ  uenza 
A expresses ligands that require CD14 for immune cell 
activation [20], CD14 seems redundant in the host 
defense response against inﬂ  uenza A virus.
Conclusion
CD14 plays a central role in the lung in the recognition 
and binding of a variety of (myco)bacterial and viral 
components, and in the ampliﬁ  cation of subsequent host 
responses. Th   e studies discussed in this chapter indicate 
that the contribution of CD14 to the pulmonary host 
defense responses may range from beneﬁ  cial to detri-
mental, depending on the microbe and the PAMPs it 
expresses. Interfering with CD14-LPS or CD14-LTA 
inter  actions reduced lung inﬂ  ammation.  Interference 
with CD14-pathogen interactions, however, did not have 
a signiﬁ  cant eﬀ  ect on M. tuberculosis or inﬂ  uenza A virus 
infection, resulted in reduced clearance of nontypeable 
H. inﬂ  uenzae, E. coli or A. baumannii in the lung, but 
enhanced clearance (and reduced dissemination) of B. 
pseudomallei or S. pneumoniae. Th  e latter observation 
indicates that certain pathogens may abuse CD14 in the 
lung to cause invasive disease. Whether CD14 is a 
suitable target for intervention in these latter infectious 
diseases and/or in aberrant inﬂ  ammatory  responses 
during pneumonia requires further study.
Abbreviations
ARDS = acute respiratory distress syndrome, BAL – broncoalveolar lavage, 
DAMP = damage/danger-associated molecular pattern, F-gp = F glycoprotein, 
GPI = glycosylphosphatidyl, GRO = growth related oncogene, HMGB-1 = 
high mobility group box-1 protein, ICAM = intracellular adhesion molecule, 
IFN = interferon, IL = interleukin, IRF = IFN regulatory transcription factor, 
LAM = lipoarabinomannan, LBP = lipopolysaccharide binding protein, 
LPS = lipopolysaccharide, LTA = lipoteichoic acid, MCP = monocyte 
chemoattractant protein, MyD88 = myeloid diff  erentiation primary-response 
protein 88, NF = nuclear factor, NK = natural killer, Nod = nucleotide-binding 
oligomerization domain containing, PAFR = platelet activating factor 
resceptor, PAMP = pathogen-associated molecular pattern, RIP = receptor-
interacting protein kinase, RSV = respiratory syncytial virus, SP = surfactant 
protein, TLR = Toll-like receptors, TNF = tumour necrosis factor, TRIF = 
TIR-domain-containing-adaptor-protein-inducing-interferon-β
Competing interests
The authors declare that they have no competing interests.
Published: 9 March 2010
References
1.  Basu S, Fenton MJ: Toll-like receptors: function and roles in lung disease. 
Am J Physiol Lung Cell Mol Physiol 2004, 286:L887-L892.
2. Wright  SD:  CD14 and innate recognition of bacteria. J Immunol 1995, 
155:6–8.
3.  LeVan TD, Von Essen S, Romberger DJ, et al.: Polymorphisms in the CD14 
gene associated with pulmonary function in farmers. Am J Respir Crit Care 
Med 2005, 171:773–779.
4.  Kim JI, Lee CJ, Jin MS, et al.: Crystal structure of CD14 and its implications 
for lipopolysaccharide signaling. J Biol Chem 2005, 280:11347–11351.
5.  Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor 
for complexes of lipopolysaccharide (LPS) and LPS binding protein. 
Science 1990, 249:1431–1433.
6.  Martin TR, Rubenfeld GD, Ruzinski JT, et al.: Relationship between soluble 
CD14, lipopolysaccharide binding protein, and the alveolar infl  ammatory 
response in patients with acute respiratory distress syndrome. Am J Respir 
Crit Care Med 1997, 155:937–944.
7.  Beutler B, Rietschel ET: Innate immune sensing and its roots: the story of 
endotoxin. Nat Rev Immunol 2003, 3:169–176.
8.  Knapp S, Florquin S, Golenbock DT, Van der Poll T: Pulmonary 
lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung 
infl  ammation in vivo. J Immunol 2006, 176:3189–3195.
9.  Pugin J, Schurer-Maly CC, Leturcq D, et al.: Lipopolysaccharide activation of 
human endothelial and epithelial cells is mediated by lipopolysaccharide-
binding protein and soluble CD14. Proc Natl Acad Sci USA 1993, 
90:2744–2748.
10.  Kitchens RL, Thompson PA: Modulatory eff  ects of sCD14 and LBP on 
LPS-host cell interactions. J Endotoxin Res 2005, 11:225–229.
11.  Park BS, Song DH, Kim HM, et al.: The structural basis of lipopolysaccharide 
recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191–1195.
12.  Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. 
Cell 2006, 124:783–801.
13.  Jiang Z, Georgel P, Du X, et al.: CD14 is required for MyD88-independent 
LPS signaling. Nat Immunol 2005, 6:565–570.
14.  Kurt-Jones EA, Popova L, Kwinn L, et al.: Pattern recognition receptors TLR4 
and CD14 mediate response to respiratory syncytial virus. Nat Immunol 
2000, 1:398–401.
15.  Chaby R, Garcia-Verdugo I, Espinassous Q, Augusto: LA Interactions between 
LPS and lung surfactant proteins. J Endotoxin Res 2005, 11:181–185.
16.  Senft AP, Korfhagen TR, Whitsett JA, Shapiro SD, LeVine AM: Surfactant 
protein-D regulates soluble CD14 through matrix metalloproteinase-12. 
J Immunol 2005, 174:4953–4959.
17.  Pugin J, Heumann ID, Tomasz A, et al.: CD14 is a pattern recognition 
receptor. Immunity 1994, 1:509–516.
18.  Schroder NW, Morath S, Alexander C, et al.: Lipoteichoic acid (LTA) of 
Streptococcus pneumoniae and Staphylococcus aureus activates immune 
cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein 
(LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 
2003, 278:15587–15594.
19.  Dziarski R, Gupta D: Peptidoglycan recognition in innate immunity. 
J Endotoxin Res 2005, 11:304–310.
20.  Lee HK, Dunzendorfer S, Soldau K, Tobias PS: Double-stranded 
RNA-mediated TLR3 activation is enhanced by CD14. Immunity 2006, 
24:153–163.
21.  Ishii Y, Wang Y, Haziot A, et al.: Lipopolysaccharide binding protein and 
CD14 interaction induces tumor necrosis factor-alpha generation and 
neutrophil sequestration in lungs after intratracheal endotoxin. Circ Res 
1993, 73:15–23.
22.  Smith LS, Kajikawa O, Elson G, et al.: Eff  ect of Toll-like receptor 4 blockade on 
pulmonary infl  ammation caused by mechanical ventilation and bacterial 
endotoxin. Exp Lung Res 2008, 34:225–243.
23.  Tasaka S, Ishizaka A, Yamada W, et al.: Eff  ect of CD14 blockade on 
endotoxin-induced acute lung injury in mice. Am J Respir Cell Mol Biol 2003, 
29:252–258.
24.  Jeyaseelan S, Chu HW, Young SK, Freeman MW, Worthen GS: Distinct roles of 
pattern recognition receptors CD14 and Toll-like receptor 4 in acute lung 
Anas et al. Critical Care 2010, 14:209 
http://ccforum.com/content/14/2/209
Page 7 of 8injury. Infect Immun 2005, 73:1754–1763.
25.  Knapp S, Wieland CW, Florquin S, et al.: Diff  erential roles of CD14 and toll-
like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit 
Care Med 2006, 173:122–129.
26.  Brass DM, Hollingsworth JW, McElvania-Tekippe E, et al.: CD14 is an essential 
mediator of LPS induced airway disease. Am J Physiol Lung Cell Mol Physiol 
2007, 293:L77–L83.
27.  Hollingsworth JW 2nd, Cook DN, Brass DM, et al.: The role of Toll-like 
receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med 
2004, 170:126–132.
28.  Knapp S, von Aulock S, Leendertse M, et al.: Lipoteichoic acid-induced lung 
infl  ammation depends on TLR2 and the concerted action of TLR4 and the 
platelet-activating factor receptor. J Immunol 2008, 180:3478–3484.
29.  Dessing MC, Schouten M, Draing C, et al.: Role played by Toll-like receptors 2 
and 4 in lipoteichoic acid-induced lung infl  ammation and coagulation. 
J Infect Dis 2008, 197:245–252.
30.  Wieland CW, Florquin S, Maris NA, et al.: The MyD88-dependent, but not the 
MyD88-independent, pathway of TLR4 signaling is important in clearing 
nontypeable haemophilus infl  uenzae from the mouse lung. J Immunol 
2005, 175:6042–6049.
31.  Wang X, Moser C, Louboutin JP, et al.: Toll-like receptor 4 mediates innate 
immune responses to Haemophilus infl  uenzae infection in mouse lung. 
J Immunol 2002, 168:810–815.
32.  Frevert CW, Matute-Bello G, Skerrett SJ, et al.: Eff  ect of CD14 blockade in 
rabbits with Escherichia coli pneumonia and sepsis. J Immunol 2000, 
164:5439–5445.
33.  Lee JS, Frevert CW, Matute-Bello G, et al.: TLR-4 pathway mediates the 
infl  ammatory response but not bacterial elimination in E. coli pneumonia. 
Am J Physiol Lung Cell Mol Physiol 2005, 289:L731-L738.
34.  Jeyaseelan S, Young SK, Fessler MB, et al.: Toll/IL-1 receptor domain-
containing adaptor inducing IFN-beta (TRIF)-mediated signaling 
contributes to innate immune responses in the lung during Escherichia 
coli pneumonia. J Immunol 2007, 178:3153–3160.
35.  Cai S, Zemans RL, Young SK, Worthen GS, Jeyaseelan S: Myeloid 
diff  erentiation protein-2-dependent and -independent neutrophil 
accumulation during Escherichia coli pneumonia. Am J Respir Cell Mol Biol 
2009, 40:701–709.
36.  Ramphal R, Balloy V, Jyot J, et al.: Control of Pseudomonas aeruginosa in the 
lung requires the recognition of either lipopolysaccharide or fl  agellin. 
J Immunol 2008, 181:586–592.
37.  Reddi K, Phagoo SB, Anderson KD, Warburton D: Burkholderia cepacia-
induced IL-8 gene expression in an alveolar epithelial cell line: signaling 
through CD14 and mitogen-activated protein kinase. Pediatr Res 2003, 
54:297–305.
38.  Branger J, Knapp S, Weijer S, et al.: Role of Toll-like receptor 4 in 
gram-positive and gram-negative pneumonia in mice. Infect Immun 2004, 
72:788–794.
39.  Wiersinga WJ, Wieland CW, Dessing MC, et al.: Toll-like receptor 2 impairs 
host defense in gram-negative sepsis caused by Burkholderia 
pseudomallei (Melioidosis). PLoS Med 2007, 4:e248.
40.  Wiersinga WJ, de Vos AF, Wieland CW, et al.: CD14 impairs host defense 
against gram-negative sepsis caused by Burkholderia pseudomallei in 
mice. J Infect Dis 2008, 198:1388 –1397.
41.  Dessing MC, Knapp S, Florquin S, De Vos AF, Van der Poll T: CD14 facilitates 
invasive respiratory tract infection by Streptococcus pneumoniae. Am J 
Respir Crit Care Med 2007, 175:604–611.
42.  Knapp S, Wieland CW, Murawskian ‘t Veer C, et al.: Toll-like receptor 2 plays a 
role in the early infl  ammatory response to murine pneumococcal 
pneumonia but does not contribute to antibacterial defense. J Immunol 
2004, 172:3132–3138.
43.  Rijneveld AW, Weijer S, Florquin S, et al.: Improved host defense against 
pneumococcal pneumonia in platelet-activating factor receptor-defi  cient 
mice. J Infect Dis 2004, 189:711–716.
44.  Wieland CW, Van der Windt GJ, Wiersinga WJ, Florquin S, Van der Poll T: CD14 
contributes to pulmonary infl  ammation and mortality during murine 
tuberculosis. Immunology 2008, 125:272–279.
45.  Reiling N, Holscher C, Fehrenbach A, et al.: Toll-like receptor (TLR)2- and 
TLR4-mediated pathogen recognition in resistance to airborne infection 
with Mycobacterium tuberculosis. J Immunol 2002, 169:3480–3484.
46.  Abel B, Thieblemont N, Quesniaux VJ, et al.: Toll-like receptor 4 expression is 
required to control chronic Mycobacterium tuberculosis infection in mice. 
J Immunol 2002, 169:3155–3162.
47.  Drennan MB, Nicolle D, Quesniaux VJ, et al.: Toll-like receptor 2-defi  cient 
mice succumb to Mycobacterium tuberculosis infection. Am J Pathol 2004, 
164:49–57.
48.  Branger J, Leemans JC, Florquin S, et al.: Toll-like receptor 4 plays a 
protective role in pulmonary tuberculosis in mice. Int Immunol 2004, 
16:509–516.
49.  Murawski MR, Bowen GN, Cerny AM, et al.: Respiratory syncytial virus 
activates innate immunity through Toll-like receptor 2. J Virol 2009, 
83:1492–1500.
50.  Dessing MC, Van der Sluijs KF, Florquin S, Van der Poll T: CD14 plays a limited 
role during infl  uenza A virus infection in vivo. Immunol Lett 2007, 
113:47–51.
Anas et al. Critical Care 2010, 14:209 
http://ccforum.com/content/14/2/209
doi:10.1186/cc8850
Cite this article as: Anas A, et al.: Role of CD14 in lung infl  ammation and 
infection. Critical Care 2010, 14:209.
Page 8 of 8